|
EP0244364A3
(en)
*
|
1986-04-30 |
1992-04-01 |
Sandoz Ag |
Preparation of olefinic compounds
|
|
PT85662B
(pt)
*
|
1986-09-10 |
1990-06-29 |
Sandoz Sa |
Processo para a preparacao de derivados de aza-indol e de indolizina e de composicoes farmaceuticas que os contem
|
|
US4898949A
(en)
*
|
1987-02-25 |
1990-02-06 |
Bristol-Myers Company |
Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
|
|
US4897490A
(en)
*
|
1987-02-25 |
1990-01-30 |
Bristol-Meyers Company |
Antihypercholesterolemic tetrazole compounds
|
|
US5300252A
(en)
*
|
1987-03-13 |
1994-04-05 |
Fmc Corporation |
Ether free organometallic amide compositions
|
|
US5091378A
(en)
*
|
1987-05-22 |
1992-02-25 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
|
|
US4761419A
(en)
*
|
1987-12-07 |
1988-08-02 |
Warner-Lambert Company |
6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
|
|
US4868185A
(en)
*
|
1987-12-10 |
1989-09-19 |
Warner-Lambert Company |
6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
|
|
US4822799A
(en)
*
|
1988-01-27 |
1989-04-18 |
Sandoz Pharm. Corp. |
Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
|
|
NO890522L
(no)
*
|
1988-02-25 |
1989-08-28 |
Bayer Ag |
Substituerte imidazolinoner og imidazolinthioner.
|
|
IT1226726B
(it)
*
|
1988-07-29 |
1991-02-05 |
Zambon Spa |
Composti attivi come inibitori della biosintesi del colesterolo.
|
|
US5196440A
(en)
*
|
1988-07-29 |
1993-03-23 |
Zambon Group S.P.A. |
Compounds active as inhibitors of the cholesterol biosynthesis
|
|
US5010205A
(en)
*
|
1988-08-23 |
1991-04-23 |
Bristol-Myers Company |
Antihypercholesterolemic tetrazol-1-yl intermediates
|
|
US4870187A
(en)
*
|
1988-08-23 |
1989-09-26 |
Bristol-Myers Company |
Antihypercholesterolemic tetrazol-1-yl compounds
|
|
US5506219A
(en)
*
|
1988-08-29 |
1996-04-09 |
E. R. Squibb & Sons, Inc. |
Pyridine anchors for HMG-CoA reductase inhibitors
|
|
NL8902441A
(nl)
*
|
1988-10-03 |
1990-05-01 |
Glaxo Group Ltd |
Chemische verbinding.
|
|
SG139553A1
(en)
*
|
1988-10-13 |
2008-02-29 |
Novartis Ag |
7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof
|
|
US5185351A
(en)
*
|
1989-06-14 |
1993-02-09 |
Smithkline Beecham Corporation |
Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
|
|
US5312828A
(en)
*
|
1989-06-14 |
1994-05-17 |
Finkelstein Joseph A |
Substituted imidazoles having angiotensin II receptor blocking activity
|
|
ES2207091T3
(es)
*
|
1989-06-14 |
2004-05-16 |
Smithkline Beecham Corporation |
Acido imidazolil-alquenoico.
|
|
US5418250A
(en)
*
|
1989-06-14 |
1995-05-23 |
Smithkline Beecham Corporation |
Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
|
|
US4970221A
(en)
*
|
1989-07-28 |
1990-11-13 |
E. R. Squibb & Sons, Inc. |
3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
|
|
US5106992A
(en)
*
|
1989-07-28 |
1992-04-21 |
E. R. Squibb & Sons, Inc. |
3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
|
|
AU637408B2
(en)
*
|
1989-10-10 |
1993-05-27 |
Glaxo Group Limited |
Substituted N-vinyl imidazole derivatives.
|
|
US5177096A
(en)
*
|
1989-10-25 |
1993-01-05 |
Smithkline Beecham Corporation |
Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof
|
|
IT1237792B
(it)
*
|
1989-12-21 |
1993-06-17 |
Zambon Spa |
Composti attivi come inibitori dell'enzima hmg-coa reduttasi
|
|
IT1237793B
(it)
*
|
1989-12-21 |
1993-06-17 |
Zambon Spa |
Composti attivi come inibitori dell'enzima hmg-coa reduttasi
|
|
US5049577A
(en)
*
|
1990-01-29 |
1991-09-17 |
E. R. Squibb & Sons, Inc. |
2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
|
|
EP0442448A3
(en)
|
1990-02-13 |
1992-08-12 |
Bristol-Myers Squibb Company |
Heterocyclic carboxylic acids and esters
|
|
US5011851A
(en)
*
|
1990-02-13 |
1991-04-30 |
Bristol-Myers Squibb Co. |
Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
|
|
US5049578A
(en)
*
|
1990-03-09 |
1991-09-17 |
E. R. Squibb & Sons, Inc. |
1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
|
|
GB9213934D0
(en)
*
|
1992-06-30 |
1992-08-12 |
Smithkline Beecham Corp |
Chemical compounds
|
|
US5728842A
(en)
*
|
1992-06-30 |
1998-03-17 |
Smithkline Beecham Corporation |
Substituted imidazolyl-alkylthio-alkanoic acids
|
|
FR2696746B1
(fr)
*
|
1992-10-12 |
1994-11-18 |
Synthelabo |
Dérivés de l'acide benzèneborinique, leur préparation et leur utilisation comme intermédiaires de synthèse.
|
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
|
AU2001257022B2
(en)
*
|
2000-04-13 |
2005-02-03 |
Mayo Foundation For Medical Education And Research |
Abeta 42 lowering agents
|
|
US7276249B2
(en)
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
|
WO2002083066A2
(en)
|
2001-04-11 |
2002-10-24 |
Bristol-Myers Squibb Company |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
|
AU2002348469B2
(en)
|
2001-10-18 |
2008-03-13 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
|
US6806381B2
(en)
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
|
AU2002348276A1
(en)
|
2001-11-16 |
2003-06-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
|
AU2003225305A1
(en)
|
2002-05-08 |
2003-11-11 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
|
AU2003241477A1
(en)
|
2002-06-10 |
2003-12-22 |
Elan Pharma International, Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
|
AU2003282983A1
(en)
|
2002-10-23 |
2004-05-13 |
Bristol-Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
|
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
|
JP2006513186A
(ja)
|
2002-12-20 |
2006-04-20 |
ファイザー・プロダクツ・インク |
Cetp阻害剤およびhmg−coaレダクターゼ阻害剤を含む剤形
|
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
|
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
|
EP2769745B1
(en)
|
2003-05-21 |
2016-05-04 |
JMS Co., Ltd. |
A blood component separator and a method for preparing a serum
|
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
|
US20050042284A1
(en)
*
|
2003-07-11 |
2005-02-24 |
Myriad Genetics, Incorporated |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
WO2005051298A2
(en)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
|
SI1725234T1
(sl)
|
2004-03-05 |
2013-04-30 |
The Trustees Of The University Of Pennsylvania |
Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
US20050252144A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Macdonald Robert A |
Veneers for walls, retaining walls and the like
|
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
US7145040B2
(en)
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
|
WO2006020853A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
|
US7517991B2
(en)
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
WO2006076598A2
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
WO2006076569A2
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
US7368458B2
(en)
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
WO2006078697A1
(en)
|
2005-01-18 |
2006-07-27 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
|
WO2006087630A2
(en)
*
|
2005-02-16 |
2006-08-24 |
Warner-Lambert Company Llc |
OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
|
|
EP2527337A1
(en)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
|
TW200726765A
(en)
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
|
US7317012B2
(en)
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
|
US7629342B2
(en)
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
|
EA200800360A1
(ru)
*
|
2005-07-22 |
2008-06-30 |
Мириад Дженетикс, Инк. |
Формуляции с высоким содержанием лекарства и дозированные формы
|
|
AR056155A1
(es)
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
|
US7488725B2
(en)
|
2005-10-31 |
2009-02-10 |
Bristol-Myers Squibb Co. |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
US8367112B2
(en)
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
|
US20100022457A1
(en)
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
|
WO2008006099A2
(en)
*
|
2006-07-07 |
2008-01-10 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
|
IN2009KN04568A
(da)
|
2007-06-01 |
2015-08-28 |
Univ Princeton |
|
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
|
JP2010534722A
(ja)
|
2007-07-27 |
2010-11-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼ活性化薬およびその使用方法
|
|
MX2010003117A
(es)
|
2007-09-20 |
2010-04-01 |
Irm Llc |
Compuestos y composiciones como moduladores de la actividad de gpr119.
|
|
GB2466912B
(en)
*
|
2007-11-29 |
2012-01-04 |
Hospital For Sick Children |
Compositions and methods for treating lysosomal disorders
|
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
|
KR20110135411A
(ko)
|
2009-03-27 |
2011-12-16 |
브리스톨-마이어스 스큅 컴퍼니 |
Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
|
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
JP2013507366A
(ja)
|
2009-10-09 |
2013-03-04 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Gpr119活性モジュレーターとしての化合物および組成物
|
|
CN102711738A
(zh)
|
2009-11-13 |
2012-10-03 |
百时美施贵宝公司 |
质量得以减小的二甲双胍制剂
|
|
CA3002948C
(en)
|
2009-11-13 |
2020-10-27 |
Astrazeneca Uk Limited |
Immediate release tablet formulations
|
|
HRP20181347T1
(hr)
|
2009-11-13 |
2018-10-19 |
Astrazeneca Ab |
Formulacije dvoslojne tablete
|
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
|
JP2013523894A
(ja)
|
2010-04-14 |
2013-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼアクチベーターおよびその使用方法
|
|
JP6042330B2
(ja)
|
2010-07-09 |
2016-12-14 |
ビーエイチヴィ ファーマ、インコーポレイテッド |
レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時/遅延放出送達システム
|
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
|
RU2015123738A
(ru)
|
2012-11-20 |
2017-01-10 |
Лексикон Фармасьютикалз, Инк. |
Ингибиторы котранспортера натрий-глюкозы 1
|
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
|
KR20170138570A
(ko)
|
2015-04-30 |
2017-12-15 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
|
|
SG11202100417RA
(en)
|
2018-07-19 |
2021-02-25 |
Astrazeneca Ab |
Methods of treating hfpef employing dapagliflozin and compositions comprising the same
|
|
CA3113037A1
(en)
|
2018-09-26 |
2020-04-02 |
Lexicon Pharmaceuticals, Inc. |
Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis
|
|
EP4188372A1
(en)
|
2020-07-29 |
2023-06-07 |
Amryt Pharmaceuticals Inc. |
Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
|
|
WO2025147589A1
(en)
|
2024-01-05 |
2025-07-10 |
Osanni Bio, Inc. |
Implants, compositions, and methods for treating retinal diseases and disorders
|